In addition to the well-known modulation of immune and inflammatory responses, the interleukin-1 (IL-1) system has been shown to be involved in the regulation of anterior pituitary hormone secretion and growth. We previously demonstrated that IL-1 receptor antagonist (IL-1ra) is expressed in human pituitary adenomas cultured in vitro. In the present study, we investigated the regulation of IL-1ra protein by IL-1␤ (1-100 U/mL) in human somatotroph adenomas (n ϭ 9) cultured for 12-48 h. IL-1␤ significantly enhanced the concentration of IL-1ra dose dependently in the somatotroph adenoma cell lysates, whereas IL-1ra concentrations remained unchanged in the culture supernatants. Furthermore, basal IL-1ra concentrations were significantly higher in the cell lysates compared with the corresponding culture supernatants. The regulation of IL-1ra in somatotroph adenoma cells is different from human cultured monocytes, in which IL-1␤ significantly stimulated IL-1ra secretion into the culture supernatants, and no change of intracellular IL-1ra content was observed. Incubation of the somatotroph adenoma cells with 100 U/mL IL-1␤ did not result in a change of GH concentrations in the culture supernatants. Enhancement of intracellular IL-1ra protein by IL-1␤ may represent a mechanism intrinsic to somatotroph adenoma cells to counterregulate the response to IL-1␤ on hormone secretion or cellular growth. (J Clin Endocrinol Metab 83: 2429 -2434, 1998 
significantly higher in the cell lysates compared with the corresponding culture supernatants. The regulation of IL-1ra in somatotroph adenoma cells is different from human cultured monocytes, in which IL-1␤ significantly stimulated IL-1ra secretion into the culture supernatants, and no change of intracellular IL-1ra content was observed. Incubation of the somatotroph adenoma cells with 100 U/mL IL-1␤ did not result in a change of GH concentrations in the culture supernatants. Enhancement of intracellular IL-1ra protein by IL-1␤ may represent a mechanism intrinsic to somatotroph adenoma cells to counterregulate the response to IL-1␤ on hormone secretion or cellular growth. (J Clin Endocrinol Metab 83: 2429 -2434, 1998) C YTOKINES have been demonstrated to be critically involved in neuroendocrine-immune interactions (reviewed in Refs. 1 and 2). The anterior pituitary gland not only represents a target but also a site of origin of cytokines. Among other cytokines, production of the inflammatory cytokine interleukin-1 (IL-1) was demonstrated in rat and mouse pituitary, increasing after treatment with bacterial lipopolysaccharide of the animals (3, 4) . Furthermore, IL-1 receptors and messenger RNA (mRNA) were characterized in mouse and rat anterior pituitary cells as well as mouse AtT-20 corticotrophs (57). Because the predominant subpopulation of mouse anterior pituitary cells that express types I and II IL-1 receptors corresponds to GH-synthesizing cells (7) , somatotrophs may be a preferential target for IL-1 actions within the pituitary. As for the human anterior pituitary, IL-1␤ expression was detected in pituitary adenomas (8) by RT-PCR of RNA. IL-6 synthesis, secretion, and immunoreactivity have been detected in human pituitary adenomas (9) . Moreover, we have described IL-2 and IL-2 receptor expression by human corticotroph adenoma cells and murine AtT-20 corticotrophs (10) and also detected mRNA expression of the intracellular IL-1 receptor antagonist (IL1ra) by RT-PCR in human pituitary adenomas as well as IL-1ra colocalized with ACTH and GH immunoreactivity in corticotroph and somatotroph tumor cells, respectively (11) .
The IL-1ra constitutes a member of the IL-1 family that neutralizes the actions of IL-1 by binding to both types of IL-1 receptors during endotoxemia or inflammatory processes (reviewed in Ref. 12) . Whereas the soluble form of IL-1ra is mainly expressed by activated monocytes and macrophages (reviewed in Ref. 12), the intracellular IL-1ra variant (13) , is expressed in various tissues of epithelial or stromal origin (reviewed in Ref. 12 ). In addition, a second biologically active form of the intracellular IL-1ra containing an additional inframe 63-bp sequence has been characterized and referred to as intracellular IL-1ra type II (14) . Several studies indicate that IL-1 and IL-1ra are differentially regulated (15) (16) (17) (18) (19) and IL-1 has been shown to stimulate soluble IL-1ra in monocytes and synovial fibroblasts (16, 20) as well as intracellular IL-1ra in human retinal pigment epithelial cells (21) .
IL-1 modulates hormone secretion at the level of hypothalamus, pituitary and peripheral glands (reviewed in Ref. 1) . Concerning the effects of IL-1 on pituitary GH secretion however, both the in vitro and in vivo data are controversial and seem to depend on the experimental conditions used (22) (23) (24) (25) (26) (27) (28) . On the other hand, it is established that GH augments the host's response and resistance to infectious agents such as Salmonella typhimurium and Listeria monocytogenesis (29, 30) and enhances a number of immune responses that are important in providing protective immunity to the host (reviewed in Refs. [31] [32] [33] . In addition to their effects on pituitary hormone secretion, there is increasing evidence that cytokines have growth-regulating properties at the level of the pituitary gland. We have previously demonstrated that IL-1, IL-2, and IL-6 inhibit the growth of normal rat anterior pituitary cells, whereas IL-1 does not regulate rat mammosomatotroph GH 3 tumor cell growth (25) , and IL-2 and IL-6 even stimulate the proliferation of GH 3 cells (34) . In line with this observation, it has recently been shown that IL-2 induces the growth of human somatotroph adenoma cells (35) .
Because anterior pituitary function has been shown to be regulated by IL-1, and somatotrophs seem to be a preferential target for IL-1 actions on the pituitary, we investigated whether the IL-1ra protein and GH secretion are regulated by IL-1␤ in human somatotroph adenomas cultured in vitro. Our data, showing that IL-1␤ enhances intracellular IL-1ra content but not GH secretion, suggest the presence of an intrinsic counterregulatory pathway limiting the secretory response of anterior pituitary cells to IL-1.
Methods

Pituitary adenomas
Pituitary adenoma tissue from nine patients with acromegaly (numbered consecutively Tu 1 to Tu 9), obtained at transsphenoidal microsurgery was studied. The diagnosis of acromegaly was confirmed by dynamic endocrine testing, and the tumor visualized by magnetic resonance imaging as previously described (36) . The preoperative clinical data and basal hormone levels of the patients with pituitary adenomas are shown in Table 1 .
Cell culture
Material and reagents, except where stated, were from Biochrom Seromed (Berlin, Germany), Gibco BRL Life Technologies (Eggenstein, Germany), Flow Labs. (Meckenheim, Germany), Falcon (Heidelberg, Germany), and Nunc (Wiesbaden, Germany). Pituitary cell culture was performed as previously described (10, 11, 25) . In brief, the tissue was washed several times with preparation buffer (137 mmol/L NaCl, 5 mmol/L KCl, 0.7 mol/L Na 2 HPO 4 , 10 mmol/L glucose, 15 mmol/L HEPES, pH 7.3, 2.5 mg/L amphotericin B and 10 5 U/L penicillin/ streptomycin). Sliced fragments were mechanically and enzymatically dispersed in preparation buffer containing 1000 U/mL collagenase (Worthington Biochemical, Freehold, NJ), 4 g/L BSA, 10 mg/L DNase II, 1 g/L soybean trypsin inhibitor, and 2 g/L hyaluronidase. Cells were centrifuged and resuspended in DMEM, pH 7.3, containing 10% FCS, 2.2 g/L NaHCO 3 , 10 mmol/L HEPES, 2 mmol/L glutamine, 10 mL/L nonessential amino acids, 10 mL/L MEM vitamins, 2.5 mg/L amphotericin B and 10 5 U/L penicillin/streptomycin, 5 mg/L insulin, 20 g/L sodium selenite, 5 mg/L transferrin, and 30 pmol/L T 3 . Between 3 and 60 ϫ 10 6 cells with a viability of at least 80% (acridine orange/ethidium bromide staining) were isolated, distributed (1 ϫ 10 5 cells/well) in 48-well culture plates, and incubated (37 C, 5% CO 2 ). The dispersed cells attached within 48 -72 h. The pituitary cell cultures were free of contaminating leukocytes, determined as described previously (34) . Fortysix days after plating, the cells were washed twice with DMEM and incubated with 1100 U/mL human recombinant IL-1␤ (Boehringer, Mannheim, Germany) for the indicated times in 440 L/well of stimulation medium (DMEM containing 2.2 g/L NaHCO 3 , 10 mmol/L Hepes, 2 mmol/L glutamine, 2.5 mg/L amphotericin B and 10 5 U/L penicillin/sptreptomycin, 0.1% BSA, and ascorbic acid). After the incubation periods, supernatants were removed for IL-1ra protein immunoassay. Cells were then rinsed twice with PBS and lysed by three freeze-thaw cycles in 440 L PBS with 0.1% BSA and 400 kIU/mL aprotinin (Bayer, Leverkusen, Germany). Human peripheral monocytes from three normal subjects obtained from isolated peripheral blood mononuclear cells were purified by plastic adherence as previously described (37) and stimulated for 12, 24, and 48 h with 1100 U/mL IL-1␤ in RPMI-1640 medium (440 L/well). Supernatants and lysates of the monocytes were obtained as for the pituitary tumor cells. Conditioned media and cell lysates were centrifuged to remove particulate debris and stored at Ϫ20 C until assayed.
Determination of IL-1ra protein
IL-1ra protein in the supernatants and cell lysates was measured with a solid-phase sandwich enzyme-linked immunosorbent assay (ELISA) for human IL-1ra (R&D Systems, Minneapolis, MN) used in previous studies (37, 38) . According to the manufacturer the ELISA shows no cross-reactivity with other cytokines like IL-1␣, IL-1␤, IL-6 or tumor necrosis factor-␣, and other studies (39, 40) demonstrated that the ELISA recognizes both forms of the IL-1ra. In control experiments, no crossreactivity with the human recombinant IL-1␤ used, GH, or FCS was detected. The least detectable concentration of IL-1ra was 8.5 pg/mL. The intraassay coefficient of variation was 5.7% and the interassay coefficient of variation was 4.9%. Blank values of optical density were automatically subtracted from the levels obtained for the dilution series for standards, and from the levels obtained for the samples. Standards and cell culture supernatants were diluted in DMEM for the pituitary cells or RPMI-1640 medium for human monocytes, which did not contain FCS, glutamine, or antibiotics.
Determination of human GH
GH levels in cell culture supernatants were determined using a sensitive fluorescence immunometric assay, as described previously (36, 41) with minor modifications. In brief, antihuman GH monoclonal antibody clone 8B11 was adsorbed to polystyrene microtiter plates (500 ng antibody/well) in 50 mmol/L phosphate buffer, pH 9.6. After 16 h incubation at 4 C, the plates were washed, and 50 L sample (diluted 1:20 to 1:50) or standard were added. Standards were prepared by serial dilution of recombinant human GH (JRP 88/624, NIBSC, London, U.K.) in DMEM. Then, 30 ng biotinylated antihuman GH monoclonal antibody clone 7F8 in 150 L assay buffer [50 mmol/L Tris-HCl, 150 mmol/L NaCl, 0.5% BSA, 0.05% (wt/vol) bovine ␥-globulin, 0.05% Tween-40, 0.05% NaN 3 and 20 mol/L diethylenetriaminepentaacetic acid, pH 7.75], were added. After 2 h of incubation at room temperature, the plates were washed again, and 10 ng streptavidin-europium conjugate (Wallac Oy, Turku, Finland), dissolved in assay buffer, were added to each well (final volume, 200 L). After an incubation period of 30 min at room temperature and a final wash step, 200 L europium fluorescence enhancement solution (Wallac Oy) were added, and the europium signal was measured in a time-resolved fluorometer (DELFIA, Wallac Oy). The working range for cell culture standards was 0.12-100 ng/mL, with an intraassay coefficient of less than 10%. 
Statistical analysis
Results are expressed as mean Ϯ sd. Each experimental condition was performed in triplicate. Statistical analysis was made using the one-way ANOVA in combination with the Scheffe's post hoc test. P Ͻ 0.05 was considered significant.
Results
IL-1␤ stimulates IL-1ra in lysates of cultured human somatotroph adenoma cells
In the lysates of the cultured somatotroph tumor cells, we observed a significant enhancement of IL-1ra concentrations by IL-1␤ in eight of the nine tumors studied. Figure 1 shows representatively the results of tumor 4 when cells were incubated with or without 1100 U/mL IL-1␤ for 24 h. The enhancement of the IL-1ra by IL-1␤ in the cell lysates was dose dependent, and there was a high interindividual variation of IL-1ra enhancement by IL-1␤ as shown in the inset of Fig. 1 , which summarizes the percent enhancement of IL-1ra by IL-1␤ of all tumors at all incubation times studied.
Different regulation of IL-1ra in lysates and supernatants of cultured human somatotroph adenoma cells by IL-1␤
In contrast to the finding of an enhancement of IL-1ra in the somatotroph adenoma cell lysates by IL-1␤ (Figs. 1 and  2) , there was no enhancement of IL-1ra by IL-1␤ in the cell culture supernatants of eight of the nine tumors. Figure 2 shows the results of all tumors when incubated for 24 h with 100 U/mL IL-1␤. Except for tumor 3, in which IL-1␤ stimulated supernatant IL-1ra, no change of IL-1ra values in the supernatants was observed also at 12 and 48 h of incubation times, as well as when the cells were incubated with 1 and 10 U/mL IL-1␤ (data not shown). There was no correlation of basal or IL-1␤-stimulated IL-1ra values in lysates or supernatants to the clinical characteristics of the patients presented in Table 1 . Basal IL-1ra concentrations were significantly higher in the lysates of the somatotroph tumor cells compared with the corresponding supernatants (Fig. 2) .
Regulation of IL-1ra by IL-1␤ in lysates and supernatants of cultured human monocytes
In contrast to the somatotroph adenoma cell cultures, a different pattern of IL-1ra regulation by IL-1␤ was observed in cultured human monocytes. In these cells, IL-1␤ significantly enhanced IL-1ra concentrations in the cell culture supernatants, whereas no change of the IL-1ra was observed in the lysates of the cultured human monocytes. Figure 3 shows the results for 24 h of incubation with or without 100 U/L IL-1␤. Similar results were obtained when the cells were incubated for 12 and 48 h with different doses of IL-1␤ (data not shown).
Effect of IL-1␤ on GH secretion in cultured human somatotroph adenoma cells
We further evaluated the effect of IL-1␤ incubation on GH secretion in the cell culture supernatants of somatotroph adenomas under our experimental conditions. Because of restricted cell numbers obtained in some pituitary adenomas, secreted GH could only be measured without and after incubation with 100 U/mL IL-1␤ in four of the nine somatotroph tumors at 24 and 48 h of incubation. No difference was observed in the concentrations of GH in the supernatants following stimulation of the cells with IL-1␤ in any of the tumors studied either at 24 h (Fig. 4) or 48 h (data not shown) of incubation.
Discussion
In this study we show that human somatotroph adenoma cells in culture contain IL-1ra protein, and that IL-1␤ enhances the content but not the secretion of IL-1ra of these cells. No change of GH secretion by IL-1␤ is observed in the somatotroph adenoma cells under the experimental conditions used. In cultured human monocytes, at 24 h of incubation, IL-1␤ does not change intracellular IL-1ra content but stimulates its secretion in the culture supernatants.
Previously, we demonstrated that human pituitary adenoma cells express intracellular IL-1ra mRNA (11) like other cells of epithelial or stromal origin (reviewed in Ref. 12 ). According to our previous observation of a colocalization of IL-1ra and human GH immunoreactivity in human somatotroph adenoma cells (11), we now demonstrate that human somatotroph adenoma cells already contain considerable amounts of IL-1ra protein, detectable by ELISA, under basal conditions. Furthermore, we show that IL-1␤ enhances IL-1ra content in pituitary tumor cells. Recently, it was shown that in response to systemic inflammation the normal mouse anterior pituitary also synthesizes IL-1ra mRNA, showing a peak at 6 h following that of IL-1␤ mRNA at 2 h (42). Because IL-1ra is induced in response to IL-1␤ in various other cell systems (16, 20, 21) , it has been proposed that IL-1␤ originating from the pituitary anterior lobe together with IL-1␤ synthesized in other sites may induce IL-1ra in the anterior lobe (42) . In the present study we provide the first experimental evidence for this proposed action of IL-1␤ on intrinsic pituitary IL-1ra synthesis.
The observation of higher basal IL-1ra concentrations as well as the enhancement of IL-1ra by IL-1␤ in cellular lysates but not in supernatants of somatotroph adenoma cells points towards the majority of newly synthesized somatotroph IL1ra remaining intracellularly, in contrast to the apparent secretion observed in cultured monocytes (15) . A predominant expression of intracellular IL-1ra in somatotroph adenoma cells may be conveyed by the cell type-specific use of the two gene promoters on alternative first exons that control expression of IL-1ra from the same gene (43) . It may also be related to the tumoral origin of the cells studied, taking into account that the normal mouse anterior pituitary has been shown to synthesize the secreted IL-1ra isoform (42) .
Because mouse and rat pituitary possesses binding sites for IL-1 or express IL-1 receptors (57), and the predominant cell type of the normal mouse anterior pituitary gland expressing p80 types I and II IL-1 receptors corresponds to somatotrophs (7), our data indicate a direct effect of IL-1␤ on somatotroph function resulting in an enhancement of IL-1ra content. Concerning the effects of IL-1 on pituitary GH secretion, however, rather controversial data were obtained previously. In nearly identical studies with rat anterior pituitary monolayer cultures it was demonstrated that IL-1␤ does not modulate GH secretion (22, 25) , whereas others showed an increase of GH secretion by IL-1␤ (23, 24) . In another study with human pituitary adenomas, the GH secretory response to IL-1 of three GH-secreting adenomas varied with stimulation in one culture, showed no significant effect in a second, and inhibition in the third (44) . Moreover, it has been shown that the effects of IL-1 on pituitary GH secretion may also be caused by a modulation of hypothalamic SRIH or GHRH secretion (45, 46) . In vivo, injection of IL-1 intracerebroventricularly or intravenously acutely suppresses plasma GH in rats (26) but not in sheep (47) , and the administration of the IL-1ra into the third ventricle reverses the suppression of plasma GH induced by lipopolysaccharide intravenously in rats (27) . In humans, a phase I trial administration of IL-1 to patients with advanced cancer has been shown to elevate circulating GH levels (28) . On the basis of our present results, the controversial data on IL-1 regulation of pituitary GH secretion found in previous studies may at least in part be attributed to different qualitative or quantitative effects of IL-1 on intrinsic pituitary IL-1ra production depending on the experimental conditions and cellular milieu. The idea that the intracellularly expressed IL-1ra inhibits intracellular IL-1 activity (13) has been underscored by demonstrating that intracellular IL-1ra possesses an intrinsic antagonistic biological activity in altering IL-1-induced gene expression at a point downstream of the initial IL-1/IL-1 receptor interaction (48) . Whereas there is no evidence that intracellular IL-1ra has a direct effect on membrane IL-1 receptor activation, it has been suggested that the previously observed IL-1 receptor desensitization of T lymphocytes to continuous IL-1 exposure does not result from changes in IL-1 receptor number or binding affinities (49) , but may be cause by an interference of the intracellular IL-1ra with the receptor-proximal transducer (48, 49) . Thus, intrinsic intracellular pituitary IL-1ra expression would neutralize the effects of IL-1 independently to the blockade of IL-1 receptors exerted by secreted IL-1ra during inflammatory responses or endotoxemia (50) . Accordingly, this mechanism would explain the lack of effect of IL-1␤ on GH secretion in vitro in the somatotroph adenomas studied.
Assuming that the inflammatory cytokine IL-1 augments circulating GH levels in man (28) , enhancement of intrinsic IL-1ra by IL-1 could be of relevance for pituitary function by reducing or blocking secretion of GH, which together with IGF-1 is supposed to represent an immunostimulatory system (reviewed in Refs. 31-33). Because we have only examined adenoma cells, however, we cannot exclude that pituitary IL-1ra expression, and its regulation by IL-1␤ in somatotrophs is exclusive for tumor cells. It may further be speculated that intrinsic expression and regulation of IL-1ra participates in pituitary tumorigenesis, because IL-1ra has been shown to antagonize the growth inhibition induced by IL-1 in normal rat pituitary cells (25) or human glioblastoma cells (51) and, on the other hand, IL-ra has been demonstrated in a human melanoma/nude mouse system to inhibit IL-1-induced augmentation of metastasis (52) .
Our finding of a regulation of the IL-1ra in human somatotroph adenoma cells by IL-1␤ point to the requirement for a tight control of the growth and hormone modulatory potential of this cytokine in somatotrophs during inflammation or the tumoral process. Although this study only addresses activity in human somatotroph adenomas, it is intriguing to speculate that the limitation of cellular IL-1 responsiveness caused by enhancement of intracellular IL-1ra also may be of potential significance in other normal or abnormal endocrine cell responses to IL-1.
